Britain’s GSK said on Friday it would limit the use of its ovarian cancer drug Zejula in the United States as a second treatment option to keep cancer at bay in patients whose tumors carry certain mutations.
The news marks a second setback for GSK’s oncology portfolio this week, after the company on Monday revealed its blood cancer drug Blenrep failed to outperform an older therapy in a key study, calling into question Blenrep’s existing U.S. approval.
The drugmaker’s shares were down nearly 5 percent on Friday afternoon.
Zejula belongs to a family of drugs called PARP inhibitors—which include AstraZeneca and Merck’s Lynparza and Clovis Oncology’s Rubraca….